Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Licensing revenue	$ 0	$ 0	$ 0	$ 850
Operating expenses:
Research and development	12,826	8,612	42,297	29,304
General and administrative	2,991	3,627	12,552	11,597
Total operating expenses	15,817	12,239	54,849	40,901
Loss from operations	(15,817)	(12,239)	(54,849)	(40,051)
Interest income	1,558	1,758	4,076	5,709
Net loss	$ (14,259)	$ (10,481)	$ (50,773)	$ (34,342)
Net loss per share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.34)	$ (0.25)
Basic and diluted weighted average shares outstanding (in shares)	168,782	137,589	148,545	137,263
Other comprehensive loss:
Net loss	$ (14,259)	$ (10,481)	$ (50,773)	$ (34,342)
Unrealized gain on marketable securities	66	577	64	449
Comprehensive loss	$ (14,193)	$ (9,904)	$ (50,709)	$ (33,893)